Lupron
(leuprolide acetate)ApprovedSmall molecule
Leuprolide acetate is used to treat advanced prostate cancer by lowering testosterone levels, and it's also used to treat endometriosis and uterine fibroids in women by temporarily stopping the release of certain hormones.[2] Lupron is currently approved and in use across 31 indications[4].[1]
Lupron is one of 619 small molecule programs targeting Prostate Adenocarcinoma. It is currently in Approved.
31
Indications
112
Total Trials
18
Active Trials
618
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 31 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lupron
EEastern Cooperative Oncology Group
Approved
Halaven
EisaiPreclinical
DATROWAY
Daiichi SankyoPreclinical
Megace
Bristol-Myers SquibbPreclinical
MS Contin
Merck & Co.Preclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Acupan
YYonsei University
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer56 trials
Show 53 more trials
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Withdrawn·—·Phase 2·NCT00003517
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Terminated·—·Phase 2·NCT03093272·9 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03043807·26 enrolled
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Recruiting·—·Phase 2·NCT04734730·70 enrolled
Management of Castration-Resistant Prostate Cancer with Oligometastases
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2/3·NCT02685397·102 enrolled
A Study of Definitive Therapy to Treat Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02716974·26 enrolled
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Completed·—·Phase 2·NCT02770391·54 enrolled
Metastatic Prostate Cancer9 trials
Show 6 more trials
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT03361735·25 enrolled
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Active, not recruiting·—·Phase 2·NCT00544830·29 enrolled
Breast Cancer5 trials
Central precocious puberty3 trials
34 more indications
Radiotherapy2 trials
Alzheimer's Disease2 trials
Prostate Adenocarcinoma2 trials
Cognition1 trial
Testosterone1 trial
Postpartum Depression1 trial
Lupron1 trial
Lupron Sex Offender Therapy
Unknown status·—·Phase 2/3·NCT00220350·10 enrolled
Acanthosis Nigricans1 trial
Leiomyoma1 trial
Outcome1 trial
The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
Unknown status·ZZekai Tahir Burak Women's Health Research and Education Hospital·N/A·NCT02114645·100 enrolled
High Risk1 trial
Post-operative or Early Salvage XRT and ADT for High Risk PCa
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00949962·87 enrolled
Ovarian Granulosa Cell Tumor1 trial
Menopausal Women1 trial
Cystic1 trial
Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection
Unknown status·—·Phase 4·NCT04094467·150 enrolled
Randomized1 trial
Hematopoietic Stem Cell Transplantation1 trial
Uterine leiomyoma1 trial
Prostate1 trial
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Completed·—·Phase 2·NCT02268175·75 enrolled
Salivary Gland Cancer1 trial
Polycystic Ovarian Syndrome (PCOS)1 trial
Hypogonadotropic Hypogonadism1 trial
Prostate Carcinoma1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lupron drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for leuprolide acetate. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details